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To the Editor: Staphylococcal
isolates with reduced susceptibility to
glycopeptides, such as vancomycin
and teicoplanin, are a serious public
health problem because staphylococci
frequently show multidrug resistance,
and glycopeptides are the only
remaining effective drugs. Since the
early reports of glycopeptide-resistant
staphylococci, teicoplanin resistance
has become more common than van-
comycin resistance, particularly
among coagulase-negative staphylo-
coccal species (1-3). In cases of sta-
phylococci with reduced susceptibility
to vancomycin (vancomycin-interme-
diate staphylococci), an increasing
number of strains showing heterore-
sistance are reported (strains that con-
tain subpopulations of cells at
frequencies >10-6 for which the van-
comycin MICs are 8 µg/mL to 16 µg/
mL); homogeneous resistance still
appears to be rare (2,4-7). In northern
Greece, resistance to teicoplanin has
recently been documented in S.
haemolyticus  strains isolated from
clinical infections (8). We report the
first bloodstream infections in Greece
associated with S. aureus and S. sciuri
strains that have homogeneous inter-
mediate-resistance to vancomycin
(MIC = 8 µg/mL). 
In our department, all clinically
significant staphylococcal isolates are
screened for reduced susceptibility to
vancomycin and teicoplanin by an
agar incorporation method (9), which
has been routinely performed since
January 1999. An inoculum of 104
CFU/spot from a log-phase broth cul-
ture was spread on Mueller-Hinton
agar plates containing appropriate
antibiotic concentrations. The strains
were incubated for a full 24 hours
before the MICs were read. When a
reduced susceptibility to vancomycin
was observed (MIC 8 to 16 µg/mL),
the test was repeated for confirmation
of the result and the strains were also
tested by National Committee for
Clinical Laboratory Standards
(NCCLS) broth microdilution (9) and
E-test (AB Biodisk, Solna, Sweden)
with BHI agar (Oxoid, Ltd., Basing-
stoke, Hampshire, UK) and an inocu-
lum density adjusted to 0.5 McFarland
value. S. aureus ATCC 29213, which
had MICs for vancomycin of 1 µg/mL
and for teicoplanin of 0.5 µg/mL, was
used as a control for the estimation of
the MICs. Two vancomycin-interme-
diate staphylococcal isolates (one S.
aureus and one S. sciuri) were recov-
ered in our hospital during December
2000 and April 2001, respectively.
The organisms were identified with
the Vitek system (bioMerieux Vitek,
La Balme les Grottes, France). Slide-
coagulase test and Staph ID 32 API
system (API system, bioMerieux) con-
firmed identification. Susceptibility to
18 antimicrobial agents was evaluated
with the Vitek system according to the
recommendations of the manufacturer,
and carriage of the mecA gene was
confirmed with a polymerase chain
reaction (PCR) that amplifies a 449-bp
product.
The first strain (S. aureus) was
recovered from a 52-year-old man
who was hospitalized after a severe
traffic accident. The patient had multi-
ple injuries, including an external
laryngeal trauma, pelvic ring disrup-
tion, and various fractures of the
extremities. He underwent immediate
tracheotomy, and a neurosurgical
operation was performed to evacuate
an extracerebral hematoma. Ceftazi-
dime, clindamycin, ciprofloxacin,
metronidazole, teicoplanin, and van-
comycin were periodically adminis-
tered as prophylaxis. An oxacillin-
resistant S. aureus isolate was recov-
ered from two blood cultures 4 weeks
after the patient’s admission. The
strain was also resistant to tobramycin,
macrolides, tetracyclines, rifampicin,
and fusidic acid, and had intermediate
resistance to vancomycin (MIC 8 µg/
mL) and teicoplanin (MIC 16 µg/mL)
by all tested methods (agar dilution,
broth microdilution, and E-test). The
strain was susceptible to chloram-
phenicol, cotrimoxazole, fosfomycin,
gentamicin, kanamycin, nitrofuran-
toin, and ofloxacin. The removal of an
intravenous catheter and treatment
with gentamicin and vancomycin
eradicated the infection. 
The second strain (S. sciuri) was
recovered from a 35-year-old man
who was an intravenous drug user. He
was admitted with renal failure, elec-
trolyte disturbances, and acute respira-
tory distress, which necessitated
intubation and mechanical ventila-
tion. The patient became febrile, and
multiple courses of antibiotics (amika-
cin, cefepime, ciprofloxacin, metron-
idazole, and vancomycin, alone or in
combinations) were administered
before the S. sciuri strain was isolated.
Seven weeks after his admission, an
oxacillin-resistant S. scuiri strain that
had cross-resistance to aminoglyco-
sides, macrolides, quinolones,
rifampicin, and tetracycline was found
in subsequent blood cultures. The
MIC of the strain for vancomycin was
8 µg/mL and for teicoplanin 16 µg/mL
by the agar dilution method, and the
result was confirmed by the E-test and
the broth microdilution method. The
strain was susceptible only to cotri-
moxazole, fosfomycin, and nitrofuran-
toin. The patient improved clinically
and was subsequently discharged
on cotrimoxazole and vancomycin
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In both cases, the MICs of vanco-
mycin remained stable after repeated
subcultures in a drug-free medium.
PCR amplification showed that both
staphylococcal strains carried the
mecA gene. However, the vanA, vanB,
and vanC genes were not amplified in
any strain.
Vancomycin-intermediate staphy-
lococci have been sporadically
reported from clinical infections after
prolonged exposure to vancomycin or
preexisting infection with methicillin-
resistant staphylococci (5,7). In our
hospital, high rates of methicillin-
resistant staphylococci are detected,
and vancomycin has been the only
treatment uniformly effective against
staphylococcal infections. However,
this is the first report of infection
caused by vancomycin-intermediate S.
aureus in Greece. In addition, S. sci-
uri, a species considered taxonomi-
cally the most primitive among
staphylococci and found primarily in
rodents and primitive mammals, has
not been implicated previously in
human infections caused by vancomy-
cin-intermediate strains in our region
or elsewhere. 
Although various studies have
described staphylococci with reduced
susceptibility to vancomycin, the
existence of isolates that have the
homogeneous vancomycin-intermedi-
ate phenotype is rather limited (4-7).
In this report, the vancomycin MIC for
both staphylococcal isolates was
repeatedly 8 µg/mL, and a confluent
growth was observed after 24 hours on
Mueller Hinton agar containing van-
comycin at a concentration of 4 µg/
mL. Discrete colonies were detected
only in plates containing 6 µg/mL of
vancomycin but not in plates contain-
ing 8 µ/mL of the drug even when a
prolonged incubation of 48 hours and
an inoculum of 106 CFU/spot were
used. The Vitek system recorded cor-
rectly both isolates as having interme-
diate level of resistance to
glycopeptides; this result was particu-
larly important given the wide use of
this commercial system in many hos-
pital laboratories. However, as was
reported for previous glycopeptide-
intermediate staphylococci (2,5), both
isolates appeared to be susceptible to
vancomycin when tested by the disk
diffusion method, with zones of 15 mm
and 16 mm for the S. aureus and the S.
sciuri isolates, respectively. 
Vancomycin-resistant staphylo-
cocci had not been detected in our
hospital until December 2000. There-
fore, the emergence of vancomycin-
resistant staphylococci is a recent
development, suggesting a potential
for wider dissemination. Since the
NCCLS agar dilution method we used
is not sensitive for the detection of
heterogeneous resistance phenotypes
(7), screening for vancomycin-resis-
tant subpopulations in the vancomy-
cin-susceptible isolates (mainly those
with MIC for vancomycin of 4 µg/
mL) is important. Whether the mecha-
nisms responsible for homogeneous
intermediate resistance to vancomy-
cin in our staphylococci are similar to
those described in isolates from Japan
and elsewhere still remains to be
answered.
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